Table 1.
Baseline patient characteristics
| Characteristic | All patients (N=348)
|
|---|---|
| n (%) | |
| Median age (range), years | 59 (19–85) |
| Age ≥65 years | 97 (28) |
| Male/female | 247/101 (71/29) |
| ECOG PS | |
| 0 | 160 (46) |
| 1 | 139 (40) |
| 2 | 39 (11) |
| 3 | 8 (2) |
| 4 | 0 |
| Unknown | 2 (<1) |
| Histology | |
| Clear cell | 329 (95) |
| Non-clear cell | 19 (5) |
| Prior nephrectomya | 311 (89) |
| Most common metastatic sites | |
| Lung | 265 (76) |
| Bone | 134 (39) |
| Lymph nodes | 124 (36) |
| Liver | 88 (25) |
| Brain | 30 (9) |
| Prior systemic therapy | |
| Anti-angiogenicb | 5 (1) |
| Cytokine | 208 (60) |
| Modified risk groups based on published | |
| MSKCC dataa,c | |
| Favorable | 125 (36) |
| Intermediate | 147 (42) |
| Poor | 23 (7) |
Notes:
Number (%) of patients with missing data: prior nephrectomy =7 (2%); MSKCC risk group =53 (15%).
Included sorafenib and bevacizumab.
Modified MSKCC risk group factors were ECOG PS ≥2, low hemoglobin, and high serum calcium.16,17 Patients without prior cytokine treatment also had lactate dehydrogenase and time to interferon-α use of <1 year as risk factors.17 Patients without prior cytokine treatment were assigned to favorable, intermediate, or poor-risk groups if 0, 1 or 2, or >2 risk factors were present, respectively. Patients with prior cytokine therapy were assigned to favorable, intermediate, or poor-risk groups if 0, 1, or >1 risk factors were observed, respectively.16
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; MSKCC, Memorial Sloan Kettering Cancer Center.